ID3/#7 10:22.02

OIPE S

PATENT ATTORNEY DOCKET NO.: 044574-5098 US

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
Dario C. ALTIERI et al.)	RECEIVED
Application No.: 10/042,302)) Group Art Unit: 1636	SEP 1 0 2002
Filed: January 11, 2002) Examiner: Unassigned	TECH CENTER 1600/2900
For: Detection of Survivin in the Biological Fluids of Cancer Patients)))	
Commissioner for Patents		

Commissioner for Patents Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that any of the listed documents do not

ATTORNEY DOCKET NO. 044574-5098-US

Application No.: 10/042,302

Page 2

constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. § 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

Reg. No. 45,397

Dated: September 6, 2002

MORGAN, LEWIS & BOCKIUS LLP CUSTOMER NO.: 009629

1111 Pennsylvania Avenue, NW Washington, D.C. 20004

Telephone: (202) 739-3000 Facsimile: (202) 739-3001

OIPE 15

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449		Attorney Docket 044574-5098-US		plication No. 042,302		
		Applicants: Dario C. AL	Page 1 of 1			
		Filing Date: January 11, 2002 Group: Unassigned				
	···-	U.S. PATE	ENT DOCUMENTS			
Initial	Patent No.	Date	Name	Class	SubClass	Filing Da
			ATENT DOCUMENTS			
	Document No.	Date	Country	Class	SubClass	Translatio
	ļ. <u> </u>					
	OTHER DOCK	MENTS (Includin	g Author, Title, Date, Pe	rtinent Page	c oto)	
	Adida et al., Lancet	1908 351 882	.83	rtinent rage	3, etc.)	
	Ambrosini et al., Na			-		
	Deveraux et al., Ge					
	Gazzaniga et al., In					
			, 1999, 113: 1076-81.			
	Islam et al., Oncoge					1. /ED
	Kawasaki et al., Ca				RECE	IVED
			l. Phys., 1999, 43:1015-	19		
	Lu et al., Cancer Re				SEP 1	U_Z UUZ
	Monzo et al., J. Clin					D 40001000
	Ozen, Curr. Opin. C			——- T	ECH CENTE	H 10001531
	Reed, J. Clin. Onco					
	Roy et al., Cell, 199					
	Stein et al., J. Urol.		59			
·	Swana et al., N. Eng					
	Tanaka et al., Clin.					
	Velculescu et al., N					
···						
	<u> </u>					
				10.		
aminer		dered, whether or r	Date Con			